Karine Dubé, John Kanazawa, Christopher Roebuck, Steven Johnson, William B Carter, Lynda Dee, Beth Peterson, Kenneth M Lynn, Linden Lalley-Chareczko, Emily Hiserodt, Sukyung Kim, Daniel Rosenbloom, Brad R Evans, Melanie Anderson, Daria J Hazuda, Lisa Shipley, Kevin Bateman, Bonnie J Howell, Karam Mounzer, Pablo Tebas, Luis J Montaner
{"title":"\"我们现在就在展望未来\":在美国进行与分析治疗中断有关的艾滋病毒治愈研究时,社区对家用病毒载量检测设备的接受程度。","authors":"Karine Dubé, John Kanazawa, Christopher Roebuck, Steven Johnson, William B Carter, Lynda Dee, Beth Peterson, Kenneth M Lynn, Linden Lalley-Chareczko, Emily Hiserodt, Sukyung Kim, Daniel Rosenbloom, Brad R Evans, Melanie Anderson, Daria J Hazuda, Lisa Shipley, Kevin Bateman, Bonnie J Howell, Karam Mounzer, Pablo Tebas, Luis J Montaner","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>People with HIV (PWH) and community members have advocated for the development of a home-based viral load test device that could make analytical treatment interruptions (ATIs) less burdensome.</p><p><strong>Objective: </strong>We assessed community acceptability of a novel home-based viral load test device.</p><p><strong>Methods: </strong>In 2021, we conducted 15 interviews and 3 virtual focus groups with PWH involved in HIV cure research. We used conventional thematic analysis to analyze the data.</p><p><strong>Results: </strong>PWH viewed the home-based viral load test device as a critical adjunct in ongoing HIV cure trials with ATIs. The ability to test for viral load at home on demand would alleviate anxiety around being off ART. Participants drew parallels with glucometers used for diabetes. A preference was expressed for the home-based test to clearly indicate whether one was detectable or undetectable for HIV to mitigate risk of HIV transmission to partners. Perceived advantages of the device included convenience, sense of control, and no puncturing of veins. Perceived concerns were possible physical marks, user errors and navigating the logistics of mailing samples to a laboratory and receiving test results. Participants expressed mixed effects on stigma, such as helping normalize HIV, but increased potential for inadvertent disclosure of HIV status or ATI participation. Increasing pluri-potency of the device beyond viral load testing (e.g., CD4+ count test) would increase its utility. Participants suggested pairing the device with telemedicine and mobile health technologies.</p><p><strong>Conclusions: </strong>If proven effective, the home-based viral load test device will become a critical adjunct in HIV cure research and HIV care.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"23 1","pages":"120-135"},"PeriodicalIF":1.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519804/pdf/","citationCount":"0","resultStr":"{\"title\":\"\\\"We are looking at the future right now\\\": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States.\",\"authors\":\"Karine Dubé, John Kanazawa, Christopher Roebuck, Steven Johnson, William B Carter, Lynda Dee, Beth Peterson, Kenneth M Lynn, Linden Lalley-Chareczko, Emily Hiserodt, Sukyung Kim, Daniel Rosenbloom, Brad R Evans, Melanie Anderson, Daria J Hazuda, Lisa Shipley, Kevin Bateman, Bonnie J Howell, Karam Mounzer, Pablo Tebas, Luis J Montaner\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>People with HIV (PWH) and community members have advocated for the development of a home-based viral load test device that could make analytical treatment interruptions (ATIs) less burdensome.</p><p><strong>Objective: </strong>We assessed community acceptability of a novel home-based viral load test device.</p><p><strong>Methods: </strong>In 2021, we conducted 15 interviews and 3 virtual focus groups with PWH involved in HIV cure research. We used conventional thematic analysis to analyze the data.</p><p><strong>Results: </strong>PWH viewed the home-based viral load test device as a critical adjunct in ongoing HIV cure trials with ATIs. The ability to test for viral load at home on demand would alleviate anxiety around being off ART. Participants drew parallels with glucometers used for diabetes. A preference was expressed for the home-based test to clearly indicate whether one was detectable or undetectable for HIV to mitigate risk of HIV transmission to partners. Perceived advantages of the device included convenience, sense of control, and no puncturing of veins. Perceived concerns were possible physical marks, user errors and navigating the logistics of mailing samples to a laboratory and receiving test results. Participants expressed mixed effects on stigma, such as helping normalize HIV, but increased potential for inadvertent disclosure of HIV status or ATI participation. Increasing pluri-potency of the device beyond viral load testing (e.g., CD4+ count test) would increase its utility. Participants suggested pairing the device with telemedicine and mobile health technologies.</p><p><strong>Conclusions: </strong>If proven effective, the home-based viral load test device will become a critical adjunct in HIV cure research and HIV care.</p>\",\"PeriodicalId\":13165,\"journal\":{\"name\":\"HIV Research & Clinical Practice\",\"volume\":\"23 1\",\"pages\":\"120-135\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519804/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Research & Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/3/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Research & Clinical Practice","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景:艾滋病病毒感染者(PWH)和社区成员一直倡导开发家用病毒载量检测设备,以减轻分析治疗中断(ATI)的负担:艾滋病病毒感染者(PWH)和社区成员一直倡导开发一种家用病毒载量检测设备,以减轻分析性治疗中断(ATI)的负担:我们评估了社区对新型家用病毒载量检测设备的接受程度:2021 年,我们对参与艾滋病治愈研究的公共卫生人员进行了 15 次访谈和 3 次虚拟焦点小组讨论。我们采用传统的主题分析方法对数据进行了分析:结果:PWH 认为家用病毒载量检测设备是正在进行的 ATIs HIV 治愈试验的重要辅助工具。在家中按需检测病毒载量的能力将减轻人们对停用抗逆转录病毒疗法的焦虑。与会者将其与治疗糖尿病的血糖仪相提并论。与会者表示,他们更希望在家中进行的检测能清楚地显示是否能检测到艾滋病毒,以降低将艾滋病毒传染给伴侣的风险。他们认为该设备的优点包括方便、有控制感、无需刺穿静脉。所认为的顾虑是可能出现的物理痕迹、用户错误以及将样本邮寄到实验室和接收检测结果的后勤工作。参与者表示对污名化的影响有好有坏,例如有助于使艾滋病毒正常化,但也增加了无意中披露艾滋病毒感染状况或参与 ATI 的可能性。除了病毒载量检测(如 CD4+ 细胞计数检测)外,增加该设备的多功能性将提高其效用。与会者建议将该设备与远程医疗和移动医疗技术相结合:如果证明有效,家用病毒载量检测设备将成为艾滋病治疗研究和艾滋病护理的重要辅助工具。
"We are looking at the future right now": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States.
Background: People with HIV (PWH) and community members have advocated for the development of a home-based viral load test device that could make analytical treatment interruptions (ATIs) less burdensome.
Objective: We assessed community acceptability of a novel home-based viral load test device.
Methods: In 2021, we conducted 15 interviews and 3 virtual focus groups with PWH involved in HIV cure research. We used conventional thematic analysis to analyze the data.
Results: PWH viewed the home-based viral load test device as a critical adjunct in ongoing HIV cure trials with ATIs. The ability to test for viral load at home on demand would alleviate anxiety around being off ART. Participants drew parallels with glucometers used for diabetes. A preference was expressed for the home-based test to clearly indicate whether one was detectable or undetectable for HIV to mitigate risk of HIV transmission to partners. Perceived advantages of the device included convenience, sense of control, and no puncturing of veins. Perceived concerns were possible physical marks, user errors and navigating the logistics of mailing samples to a laboratory and receiving test results. Participants expressed mixed effects on stigma, such as helping normalize HIV, but increased potential for inadvertent disclosure of HIV status or ATI participation. Increasing pluri-potency of the device beyond viral load testing (e.g., CD4+ count test) would increase its utility. Participants suggested pairing the device with telemedicine and mobile health technologies.
Conclusions: If proven effective, the home-based viral load test device will become a critical adjunct in HIV cure research and HIV care.